Patient and tumors’ characteristics before surgery | ||
---|---|---|
N = 19 | ||
Age, years (range) | 64 | 41–81 |
Gender | No | % |
Male | 14 | 74 |
Female | 5 | 26 |
ECOG-PS | No | % |
0 | 11 | 58 |
1 | 5 | 26 |
2 | 3 | 16 |
Location of tumor | No | % |
Distal esophagus or GEJ | 8 | 42 |
Stomach | 11 | 58 |
Clinical TNM stage | No | % |
Stage I | 3 | 16 |
Stage II | 8 | 42 |
Stage III | 8 | 42 |
Stage IV | 0 | 0 |
Neoadjuvant chemotherapy | No | % |
DCF | 7 | 37 |
PET | 7 | 37 |
TFOX | 3 | 16 |
Docetaxel-Cisplatin | 1 | 5 |
Cisplatin-Paclitaxel-Doxorubicin | 1 | 5 |
Surgery and postoperative variables | ||
N = 17 | ||
Type of surgery, No (%) | No | % |
Total gastrectomy | 8 | 47 |
Subtotal gastrectomy | 2 | 12 |
Lewis–Santi esophagectomy* | 7 | 41 |
Lymphadenectomy extend | No | % |
D1 | 4 | 31 |
Modified D2 | 6 | 46 |
D2 | 3 | 23 |
Missing | 4 | – |
Resection | No | % |
R0 | 12 | 80 |
R1 | 3 | 20 |
R2 | 0 | 0 |
Missing | 2 | – |
Pathological tumor classification | No | % |
pT0 | 1 | 6 |
pT1 | 2 | 13 |
pT2 | 3 | 19 |
pT3 | 5 | 31 |
pT4 | 5 | 31 |
Missing | 1 | – |
Pathologic nodal classification | No | % |
pN0 | 2 | 13 |
pN1 | 6 | 38 |
pN2 | 3 | 19 |
pN3 | 5 | 31 |
Missing | 1 | – |
Pathologic metastatic stage | No | % |
pM0 | 15 | 88 |
pM1 | 2 | 12 |
Adjuvant treatment | No | % |
DCF | 3 | 18 |
Docetaxel-Cisplatin | 1 | 6 |
TFOX | 1 | 6 |
mFOLFOX6 | 6 | 35 |
EOX | 2 | 12 |
Chemoradiotherapy | 2 | 12 |
No adjuvant treatment | 2 | 12 |